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Abstract: Clinical risk factors associated with the development of osteoporosis and
vertebral fractures were evaluated in patients with asthma in relation to sex, age, and
dose of glucocorticoids (GC). In 75 asthmatic patients including 44 steroid-dependent
asthma, the bone mineral density (BMD) of the lumber spines was measured by
quantitative computed tomography (OCT). Thirty five patients of them were followed
up with radiographs over a period of 0.5 to 4 years (average: 2.6±1.3 years) The
BMD was significantly lower in older (p<O.01) or female (p<0.05) patients. All the
five patients developing vertebral compression fractures were female and more than 64
y.O., and received systemic glucocorticoid (GC) therapy for more than 3 years with a
lot of cumulative gramdosage of GC. No significant correlation was demonstrated
between the BMD and the dose of systemic GC per day, but multiple regression
analysis demonstrated a significant relationship (p<O.o1) between the BMD and
lifetime cumulative gramdosage of GC. Multiple regression analysis also demonstrated
significant relationships (p<O.01) between the BMD and clinical factors such as age
and sex. These results indicates that the bone loss and vertebral fractures of patients
with asthma are influenced by the patient's age, sex, and the lifetime cumulative GC
dose.
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Introduction
The pathogenesis of asthma is not related
to bone metabolism and bone mineral density
(BMD), but some patients with severe asth-
ma who had prolonged oral systemic glu-
cocorticoid (GC) therapy, and were difficult
to wean off GC, have at high risk of develop-
ing bony complications due to glucocorticoid-
SI-7). Other clinical risk factors such as age,
sex and the other underlying diseases may
also affect bone metabolism in patients with
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Table 1. Clinical details of 75 patients
with bronchial asthma
from the medical records. The dose of GC
was expressed in equivalent grams of pred-
nisolone. Thirty two patients had received
continuous inhaled GC (BDI~80011g/ day) for
at least 6 months. Eight patients had been
treated with vitamin D therapy, and 35
patients were followed up with radiographs
over a period of 0.5 to 4 years (average:
2.6±1.3 years).
asthma.
Numerous studies have reported that re-
duced BMD and progressive bone loss occur
in patients receiving long-term systemic GC
therapy" 3, 8).
The effects of GC on the skeleton are most
markedly observed in the trabecular bone I) ,
and it is assumed that 30% -50% of patients
treated for more than 1 year with 7.5 -10
mg / day of prednisolone-equivalent will de-
velop atraumatic vertebral fracture I) .
To identify clinical characteristics associ-
ated with the development of bone loss and
fractures, we investigated the trabecular bone
mineral density (BMD) of the lumber spines
in 75 asthmatic patients, including 44 steroid-
dependent asthma, using quantitative com-
puted tomography (QCT)g"O). We also stud-
ied a correlation between the BMD and daily
and lifetime cumulative gramdosages of GC
in patients with steroid-dependent asthma.
Subjects
Sex (M/F)
Age (Year)
Height(em)
Weight(kg)
BMI (kg/m2)
BMD(mg/em3)
With another disease
Systemic prednisolone-equivalent :
;;;;5mg/day
5mg/day> >Omg/day
Cumulative dose of prednisolone(g)
Inhaled steroid
15/60
64.8±10.7
152±7.5
52.5±9.6
22.7±3.7
99A±50A
14 cases
35 cases
9 cases
7.60±13.7
32 cases
The subjects in this study were 75 patients
with bronchial asthma (60 females and 15
males). The characteristics of the study
subjects are summarized in Table 1. Forty
four patients with steroid-dependent asthma
had received continuous oral systemic GC for
at least 6 months preceding the study.
Fourteen patients had medical conditions
affecting bone metabolism; such as diabetes
mellitus (n= 7), hyperthyroidism (n= 2 ),
pituitary insufficiency (n= 1), post total
gastrectomy (n= 2), post bilateral ovarian
resection (n = 3) and rheumatoid arthritis
(n= 1 ). None of the patients was alcoholic,
and none was smoker. History and physical
examination were performed in all the pa-
tients. Duration, daily and cumulative life-
time gramdosages of GC were calculated
Methods
The following clinical parameters were
evaluated in these subjects: 1) Lateral spine
radiographs for compression fractures (de-
fined as ~ 20% loss of vertebral body
height), 2) Trabecular bone mineral density
(BMD) of the lumber spines measured by
quantitative computed tomography (QCT)9,'0)
with a Toshiba X peed (Tokyo, Japan). The
average BMD of L2 - L4 was calculated.
Alternate spine (above or below) was meas-
ured if vertebral compression fracture was
suspected. The BMD was expressed as mg/en!'
CaC0 3 equivalent by means of a simultane-
ously scanned calibration phantom (Kyoto-
Kagaku B-MAS, Kyoto, Japan).
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Statistical analysis
Student's t-test, multiple regression analy-
sis and other statistical analysis were per-
formed using a software package, StatView
4.5 (Abacus Concepts).
Results
Using Student's t-test, a correlation was
evaluated between BMD and the following
clinical parameters: (1) body mass index (B
MI)(~23.0kg/nf, <23.0kg/nf), (2) age (~
65y.o., <65y.o.), (3) sex (male, female), (4)
present daily systemic GC does (~ 5 mg/day,
omg/day), (5) inhaled GC therapy, and (6)
the other underlying diseases affecting bone
metabolism. (Table 2).
Table 2. Comparison of BMD in sub-groups
of patients
Index BMD(mg/cmJ ) t-test
BM I (kg/m2) ~23.0(n=36) 98.1 ±44.9
<23.0(n=39) 100.6±55.6 N.S.
Age(year) ~6S(n=40) 79.3±41.3
<65(n=35) 122.3±50.6 p<O.Ol
Sex M(n=15) 125.S±45.0
F(n=60) 92.9±49.9 p<0.05
Systemic steroid <::Smg/day (n-35) 101.8±53.0
(prednisolone) non (n=31) 95.2±50A N.S.
Inhaled steroid use (n=32) 99.8±46.7
non-use(n=43) 96.3±51.0 N.S.
Other disease yes (n=14) 90.6±60.8
no (n=61) 102.1 ±47.8 N.S.
There was significant difference III the
BMD between older (~65 y.o.) and younger
patients «65 y.o.)(p<O.Ol). There was also
significant difference BMD between females
and males (p<O.05). There was no significant
difference in the other parameters assessed in
this study, including daily systemic GC
equivalent dose and the other underlying
diseases affecting bone metabolism.
Multiple regression analysis was also per-
formed (Table 3) to evaluate relationships
between the BMD as a dependent variable
and the following clinical parameters as
independent variables : (1) age, (2) lifetime
cumulative gramdosage of GC, (3) sex (male,
female), and (4) BMI (Table 3). Significant
relationship was demonstrated between the
dependent variable and the independent vari-
ables (R=O.651, p<O.OOl). Multiple regres-
sion analysis showed that the BMD was
oppositely proportional to age (p<O.OOl),
female (p=O.0044) and lifetime cumulative
gramdosage of GC (p=O.0056).
Table 3. Multiple regression analysis be-
tween BMD and clinical parame-
ters in patients with asthma
t, r
Independent Partial PartialRegression Standard t~value p-value
variable Error RegressionCoefficient Coefficient
Constant 256.65 42.75 256.65 6.05 <0.0001
Age ·2.44 0.46 -0.52 -5.34 <0.0001
Total dose of PSL • 1 .02 0.36 -0.26 -2.66 0.0059
Sex '36.32 12:98 -0.30 -2.95 0.0044
BMI 1.63 1.33 0.12 1.23 0.2 zz 7
P5L: prednisolone
R·0.651
R2.0.4Z4
Sex: Female.', Male:o 0 p<O.OOO1
(6140).' 2.44(Age)· 1.02(P5L dose)- 36.32(50x)+I.63(6MI)+256.65
Five of the 35 patients followed up with
radiographs developed vertebral compression
fractures (Table 4). All the five patients
with fractures were female, and more than 64
y.o., and received systemic GC therapy for
more than three years. The average cumula-
tive gramdosage of GC was 10.9 g. The
average age was 71.2 y.O. The average BMD
was 49.9mg/cnf. Their postmenopausal periods
were 15-25 years, and they had 1 - 3 chil-
dren. The incidence of vertebral fracture of
the asthmatic patients in this study was
O.055/year/case.
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Table 4. Clinical details of 35 followed
patients
The BMD in the present study was signifi-
cantly lower in older or female patients with
bronchial asthma, just like with primary
osteoporosis. Numerous studies have reported
that reduced BMD and progressive bone loss
occur in patients receiving long-term GC
therapy I. 3, 8). Side effects of GC on the skele-
ton are most markedly found in the tra-
becular bone!), and this bone loss is closely
related to fractures in the lumber spines 8 ). It
is assumed that 30% - 50% of patients
treated for more than 1 year with 7.5 -10
rng / day of prednisolone-equivalent will de-
velop atraumatic vertebral fracture 1) • It is
also suggested that the bone loss occurs
predominantly within the first 6 months of
long-term GC therapy3).
In this study, no significant relationship
was demonstrated between the BMD and the
daily systemic GC equivalent dose, but multi-
ple regression analysis demonstrated a sig-
nificant relationship between the BMD and
the lifetime cumulative gramdosage of GC.
These results indicated that the lifetime
cumulative GC dose was more important
Table 5. Clinical details of patients with
compression fracture of spine
In the present study, the incidence of verte-
bral fracture of asthmatic patients including
those treated with GC was 0.055/year/case.
This finding might suggest that vertebral
fracture unusually developed in patients with
asthma except those treated with a high
cumulative GC dose. It has been reported the
daily much dose of inhaled GC may adversely
affect bone densityll), 12), but inhaled GC at
daily doses lower than 1600Jlg/day does not
cause bone 10ss13). In the present study, all the
patients receiving continuous inhaled GC was
treated with not exceeding 800Jlg / day of
beclomethasone (BDI), and no significant
10.88
21.90
2.74
14.90
8.35
6.53
Cumulative
dose(g)
another Systemic: Periods
Case Sex Position Age(Y) BMD(mglcm.!) disease prednisolone (year)
N.M. F L4 73.9 36.2 RA 5mglday 12.0
Y.K. F LZ 71.1 57,0 2.5mglday 3.0
Y.Y. F Ll 64.7 89,2 5mglday 8.2
Y.T. F L2 68.0 48.7 5mglday 4.6
S,J, F L3 78.1 18.2 5mglday 3.6
Mean 71.2 49.9 6.3
than the daily GC dose for the pathogenesis
of GC-induced bone loss. According to this,
GC-induced bone loss could develop even in
patients with not exceeding 5.0 rng / day of
prednisolone-equivalent if they had taken a
lot of GC for a long time. These findings
emphasized the need to consider prophylaxis
against the bone loss from the outset.
All the patients who developed vertebral
compression fractures (Table 4) were fe-
male, and more than 64 y.O., and had sys-
temic GC therapy for a long time with a
high cumulative GC dose, and had reduced
BMD. These findings suggested the bone loss
and vertebral fractures of patients with
asthma were influenced by the patient's age
and sex, just like primary osteoporosis, and
by the cumulative GC dose.
16 cases
9 cases
3.71 ±3.49
12 cases
5 cases
5 cases
2.6±1.3
6/29
64.9±10.0
22.7±3.7
104.7±S1.1
Discussion
Periods for observation (year)
Sex (M/F)
Age (y.oJ
BMI (kg/mz)
BMD (mg/cm3)
Systemic prednisolone-equivalent :
;;;;Smg/day
Smg/day> >Omg/day
Cumulative dose of prednisolone(g)
Inhaled steroid
With other disease
With vitamin D therapy
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relationship was demonstrated between BMD
and inhaled GC treatment.
Spinal QCT measurements have been re-
ported to be sensitive for detecting cancellous
bone mineral loss, such as GC-induced bone
loss5) and postmenopausal bone loss. This
measurement instrument, however, is not
extremely accurate. In further study, we want
to measure with a more accurate measuring
instrument such as peripheral QCT (pQCT).
In the present study, a correlations was
evaluated between the BMD and risk factors
associated with the development of osteopo-
rosis and vertebral fractures in patients with
asthma. Further studies with more subjects
are needed to clarify the risk factors and
pathogenesis which associate with the devel-
opment of osteoporosis and vertebral frac-
tures in patients with asthma.
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要 旨
対象は気管支噛息75症例｡このうち44例はステ
ロイド依存性難治症例であった｡35症例について
は,0.5年から4年間(平均 :2.6±1.3年間)の経時
的観察もおこなわれた｡これらの症例の骨塩量に
影響を及ぼす因子について検討をおこなった｡高
齢者,女性に有意な低骨塩量を認めた｡重回帰分
析にて年齢,性別,経口副腎ステロイド投与総量
などの項目に骨塩量と有意な関連が認められた｡
また,35症例中5例に脊椎圧迫骨折が発生し,い
ずれも骨塩量が低く,高齢者,女性,長期ステロ
イド内服例であった｡これらのことから気管支鴨
息患者においては,女性,高齢者,長期ステロイ
ド内服例に骨塩量減少や脊椎圧迫骨折のリスクが
高いと考えられた｡また,ステロイド続発性骨粗
怒症の発生には,ステロイドの現在の一日内服量
よりもこれまでの総積算内服量が重要と考えられ
た｡
索引用語 :気管支鴨息,骨粗髭症,椎体骨折,ス
テロイド療法
